February 2023

Medtronic & Abbott share new TAVR data | Addressing health disparities at the local level | A risky artificial sweetener ()
FDA's warning about Trifecta heart valves | Heart attack deaths going down | A new-look device for PCI & TAVR ()
News Alert: FDA warns that early deterioration is possible with Abbott's Trifecta heart valves ()
Care Delivery Highlights: A key update on a recent recall | 4,000 TAVRs | Comprehensive heart teams ()
Daily marijuana use increases CAD risk | Ongoing trends in PAD & CLI | Cardiologist honored with her own doll ()
ChatGPT & cardiology | The rise of private equity-backed management companies | More from the last week ()
Heart Rhythm Highlights: How more AFib screening is a mixed blessing | Key approvals for Medtronic & Abbott ()
New patient-specific heart models could make a big impact | Long COVID & the heart | Recalled device returns ()
Confirmed: Long COVID more than doubles a person’s risk of heart issues ()
Why private equity-backed management companies are investing in cardiology | New ACC/AHA/SCAI training recommendations ()
3 key takeaways from a survey of cardiologists, health leaders & CVD patients | Sotagliflozin & heart failure ()
Cardiac Imaging Highlights: ICE & TEE | Intravascular imaging-guided PCI | CCTA for CAD | Much more ()
ChatGPT & cardiology: A close look at the potential of chatbots | Medtronic’s extravascular ICD gains key approval ()
Private equity investments in cardiology | ICE replacing TEE? | Understanding AI | More from the last week ()
Heart Health Highlights: FDA approves new type 2 diabetes drug | An updated look at the DASH diet ()
ACC recommends intravascular imaging during PCI | AHA President Michelle Albert | Vericiguat for HF ()
TAVR Highlights: New self-expanding valve shows promise | 4,000 TAVRs | How CAD & PCI affect outcomes ()
Q&A: Exploring the rise of private equity investments in cardiology | Why imagers need to understand AI ()
Vascular & Endovascular Highlights: ISC 2023 in review | TAVR patients with PAD face additional risks ()
COVID-19 linked to higher diabetes risk | Practice pays $2M to settle fraud allegations | CAD, PCI & TAVR ()
Interventional Cardiology Highlights: New coronary IVL recommendations | High-risk patients with complex CAD ()
4 key takeaways from ISC 2023 | PCI benefits high-risk CAD patients ineligible for CABG ()
Structural Heart Disease Highlights: ICE & TEE | The evolution of comprehensive heart teams ()
GE Healthcare to acquire Caption Health | Can ICE replace TEE? | FDA's new warning for heart patients ()
Abbott's big acquisition | ChatGPT & cardiology | Comprehensive heart teams | More from the last week ()
Heart Failure Highlights: New recommendations for acute MCS | IABPs recalled after serious injuries ()
Cardiologists put AI model ChatGPT to the test | Abbott's $890M acquisition | A busy week for investments ()
News Alert: Abbott to acquire vascular disease specialists for $890M ()
New MCS guideline examines device selection, ethical concerns & more | The latest on renal denervation ()
Comprehensive heart teams are rewriting the rules of patient care | Hospital performs 4,000th TAVR ()
TAVR & PAD | FDA clears AI-powered imaging solution | Fertility treatments & heart health ()
Economics Highlights: Shockwave Medical's new deal worth $100M | Medtronic's message to shareholders ()
AI model predicts risk of post-operative AFib | Cerebral protection devices & TAVR ()
COVID-related MIS-C | PCI without on-site surgical backup | A new recall | More from the last week ()
Social isolation, loneliness linked to HF risk | 2 key approvals for Abbott | The genes responsible for CAD ()
4 key CVIS trends | Why are post-TAVR stroke rates higher at specialty centers? | Coronary IVL ()
January's Most Popular Stories: CABG bests PCI | Damar Hamlin | A new recall | TAVR trends | Much more! ()